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Neuropeptides and metabolic hormones in OSA patients with and without EDS 1955EDS;
Metabolismpatients with OSA manifest EDS. Hypocretin-1, neuropeptide Y, leptin, ghrelin and adiponectin
are implicated in both metabolic and sleep regulation, two conditions affected by OSA. We
hypothesized that levels of these peptides may be related to EDS in OSA patients.
Methods: We included 132 patients with EDS, as defined by an Epworth Sleepiness Scale (ESS)
score 13 (mean  SD, 15.7  2.3) and 132 patients without EDS as defined by an ESS score 9
(6.5  1.9). All patients had an apneaehypopnea index (AHI)  20 h1. Both groups were
matched for gender (males; 83.3% vs. 85.6%), age (50.15  11.2 yrs vs. 50.7  9.9 yrs), body
mass index (BMI) (31.8  5.6 kg m2 vs. 32.1  4.8 kg m2), and apneaehypopnea index
(AHI) (45.5  19.1 h1 vs. 43  19.2 h1).
Results: OSA patients with EDS showed significantly higher plasma hypocretin-1 levels
(p < 0.001) and lower plasma ghrelin levels (p < 0.001) than OSA patients without EDS. There
were no statistically significant differences in neuropeptide Y (pZ 0.08), leptin (pZ 0.07) and
adiponectin (p Z 0.72) between the two groups. In the multiple linear regression model ESS
score was associated with plasma levels of hypocretin-1, ghrelin and total sleep time.
Conclusion: Our study shows that EDS in patients with OSA is associated with increased circu-
lating hypocretin-1 and decreased circulating ghrelin levels, two peptides involved in the regu-
lation of body weight, energy balance, sympathetic tone and sleepewake cycle. This
relationship is independent of AHI and obesity (two key phenotypic features of OSA).
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Obstructive sleep apnea (OSA), a disease that affects about
4% of the general population, is a chronic condition char-
acterized by repetitive collapse of the upper airway during
sleep leading to significant hypoxemia, sleep fragmenta-
tion, and excessive daytime sleepiness (EDS).1,2 The exist-
ing definition of EDS in the International Classification of
Sleep Disorders3 is based on the behavior of unintentionally
falling asleep and difficulty maintaining alertness. EDS is
considered an important health problem, leading to road
accidents, psychosocial morbidity and poor quality of life.4
EDS has been associated with cardiac dysfunction. Patients
with EDS manifest significantly lower baroreflex sensitivity
and significantly higher low-to-high frequency spectral
power ratios of heart rate variability during the various
stages of nocturnal sleep.5 Although EDS is one of the main
symptoms of sleep apnea, for unclear reasons not all
patients with OSA complain of EDS. In fact, about 15% of
patients with OSA do not report EDS.6,7 The pathogenesis of
EDS in OSA patients appears to be related to underlying
intermittent hypoxia and disrupted sleep. However, EDS is
also related to metabolic and sympathetic activities. In
a previous study, we have shown that EDS in OSA is asso-
ciated with insulin resistance, independently of obesity.8
Hypocretin-1 (also known as orexin-A) is a neuropeptide
that influences arousal and the sleepewake cycle, cardio-
vascular function, temperature, metabolic rate and loco-
motor activity.9,10 Neuropeptide Y is a neurotransmitter that
stimulates appetite and is involved in the regulation of
sympathetic activity, body weight, and energy balance.11,12
Leptin is a protein produced in adipose tissue that interacts
with receptors in the hypothalamus to inhibit eating and
control body weight and fat distribution. Ghrelin is
a stomach-derived peptide that has been related to the
regulation of body weight through stimulation of the appe-
tite. Finally, adiponectin, a hormone that is closely related to
metabolism, is secreted by adipocytes and may have both
anti-atherogenic and anti-inflammatory properties.13The aim of this study was to address determinants of
sleepiness in patients with OSA. It evaluated plasma levels
of neuropeptides (hypocretin-1 and neuropeptide Y) and
metabolic hormones (ghrelin, leptin and adiponectin) in
OSA patients and their relationship with EDS in two cohorts
of patients, one with OSA and another either with or
without EDS, matched for age, gender, apneaehypopnea
index (AHI) and body mass index (BMI). These markers are
related to energy metabolism, arousal and sympathetic
activity, pathways that are altered in OSA and that may be
associated with manifestations of EDS in OSA patients.Materials and methodsPatients
We included 132 patients with EDS and 132 patients without
EDS. All patients had an AHI  20 h1. Participants were
recruited from subjects who were seen at the sleep units of
four teaching hospitals in Spain. Both groups of patients
were matched for gender, age, BMI and AHI. Exclusion
criteria were the presence of chronic obstructive pulmo-
nary disease, chronic inflammatory intestinal diseases, liver
cirrhosis, diabetes mellitus, depression, thyroid dysfunc-
tion, rheumatoid arthritis, chronic renal failure, psychiatric
disorders, malignant tumors (particularly gastric tumors),
gastric surgery and/or the use of drugs that could affect
sleep. None of the patients were being treated with
continuous positive airway pressure (CPAP) at the time they
were enrolled in the study.
Daytime sleepiness was assessed using the Spanish
version of the Epworth Sleepiness Scale (ESS).14 ESS scores
13 were considered indicative of EDS, while ESS scores 9
were considered to represent an absence of EDS. Patients
with an ESS score higher than 9 and lower than 13 were
excluded from the study, because such ESS scores do not
allow for an accurate delineation of EDS status.
1956 M. Sa´nchez-de-la-Torre et al.All patients included in the study provided written
consent after being fully informed of the goals, methods
and potential risks of the study. The Ethics Committee of
the participating institutions approved this project.Measurements
OSA diagnoses were established by overnight poly-
somnography, which included recordings of oronasal
airflow, thoracoabdominal movements, electrocardiog-
raphy, electroculography, electroencephalography, Chin
electromyography, and arterial oxygen saturation
measurements. Apnea was defined as the absence of
airflow for more than 10 s. Hypopnea was defined as an
airflow reduction greater than 50% that lasted for more
than 10 s and resulted in arousal or oxygen desaturation
greater than 4%.15 Oronasal flow was measured with both
a nasal pressure transducer and an oronasal thermistor.
Polysomnography screening was done according to inter-
national guidelines. AHI was defined as the number of
apneas plus hypopneas per hour of sleep.
Due to the known variations in hormonal levels within
the sleep/wake cycle16 blood samples were collected in
all patients immediately after morning awakening.
Venous blood samples were obtained from an antecubital
vein using a collecting tube with ethylenediamine tetra-
acetic acid (EDTA). Blood samples were centrifuged,
and the plasma fraction was immediately separated into
aliquots and stored at 80 C until analysis. Blood in
EDTA tubes and aliquots of plasma were transported in
dry ice from participating hospitals to the Arnau de
Vilanova Hospital, and stored at 80 C pending
centralized analysis.
Plasma hypocretin-1 levels were measured using
a previously validated17 Enzyme immunoassay (EIA) system
designed for measuring hypocretin-1 in plasma (Phoenix
Pharmaceuticals, California, USA). The assay sensitivity for
hypocretin-1 was 0.22 ng/ml with intra- and inter-assay
coefficients of variation of <5% and <14%, respectively.
Specificity of the hypocretin-1 assay was 100% with no
cross-reactivity (0%) with orexin-A 16e33, agouti-related
protein 83e132-amide, neuropeptide Y, a-melanocyte
stimulating hormone or leptin. Plasma neuropeptide Y
levels were measured using an EIA system (Phoenix Phar-
maceuticals, California, USA). The assay sensitivity for
neuropeptide Y was 0.09 ng/ml. Specificity of the assay for
neuropeptide Y was 100% with no cross-reactivity (0%) with
peptide YY, pancreatic polypeptide, vasoactive intestinal
peptide (VIP), insulin, amylin or somatostatin. Ghrelin,
leptin and adiponectin plasma levels were measured using
commercially available ELISA kits (Phoenix Pharmaceuticals
Inc., Burlingame, CA; DRG Instruments GmbH, Germany;
and Mediadiagnost, Reutlingen, Germany, respectively).
Intra- and inter-assay coefficients of variation for ghrelin
were less than 5% and less than 9%, for leptin they were
6.43% and 10.1%, and for adiponectin were 3.37% and
6.05%, respectively. Measurements were always done in
duplicate, and mean values were used for analysis. Glucose
and triglyceride concentrations were determined by stan-
dard enzymatic methods using a Hitachi 917 biochemical
analyzer (Roche Diagnostics, Indianapolis, USA). Plasma C-reactive protein (CRP) was measured using a chemo-
luminescent immunometric assay (Inmunolite 2000 High
Sensitivity CRP).
Statistical analysis
Results are shown as means  standard deviations (SD).
Differences between groups were assessed by the Man-
neWhitney non-parametric test for quantitative variables
and the Fisher’s exact test for dichotomous categorical
variables. Correlations between variables of interest were
assessed using the non-parametric Spearman test.
A multivariate linear regression model was used to assess
the association of hypocretin-1, neuropeptide Y, ghrelin,
leptin and adiponectin plasma levels with ESS values,
adjusting by potential confounding factors (both known
confounding factors as well as variables differently
distributed in both study groups). Only statistically signifi-
cant variables or confounding factors were kept in the
model. All data analyses were performed using the SPSS
(version 16) statistical software. P values lower than 0.05
were considered statistically significant.
Results
Table 1 shows pertinent anthropometric and clinical data
for the two study groups. OSA was severe in both groups, as
demonstrated by their high AHI scores. Percentage of time
with SaO2 < 90% and F1 sleep was lower in patients with
excessive daytime somnolence, and total sleep time was
higher in this group.
Plasma hypocretin-1 levels were higher in patients with
EDS than in those without EDS (2.52  0.25 ng ml1 vs.
1.64  0.17 ng ml1, p < 0.001). Plasma neuropeptide Y
levels show a tendency (non-significant) to be lower in
patients with EDS (0.91  0.07 ng ml1 vs.
0.97  0.06 ng ml1, p Z 0.087) (Fig. 1). Plasma ghrelin
levels were lower in patients with EDS than in those without
EDS (6.34  3.52 ng ml1 vs. 8.94  5.74 ng ml1; p < 0.001;
Fig. 2). Plasma leptin levels were similar in patients with
and without EDS (11.45  10.6 ng ml1 vs.
10.12  13.27 ng ml1; p Z 0.071), and this was also true
for plasma adiponectin levels (5.42  2.98 mg ml1 vs.
5.47  2.78 mg ml1; p Z 0.728; Fig. 2).
We assessed the association of ESS, BMI and AHI with
neuropeptides and metabolic hormones and found that ESS
score was related to hypocretin-1 and ghrelin, and BMI was
related to leptin and ghrelin (Table 2).
The adjusted multivariate linear regression model used
to explain ESS score showed a statistically significant rela-
tionship with ghrelin and hypocretin-1 levels, together with
the total sleep time. ESS score was not associated with AHI
and BMI.
Discussion
These results show that, compared to OSA patients without
EDS, plasma levels of hypocretin-1 were elevated in OSA
patients with EDS, whereas plasma levels of ghrelin were
reduced. These relationships were independent of obesity
Table 1 Anthropometric and clinical characteristics (mean  SD) of OSA patients with and without EDS.
OSAS patients (n Z 264) p-value
With EDS (n Z 132) Without EDS (n Z 132)
Sex, m [n (%)] 110 (83.3) 113 (85.6) 0.61
Age, years 50.15 (11.27) 50.72 (9.96) 0.797
BMI*, Kg/m
2
31.85 (5.68) 32.18 (4.84) 0.191
Epworth Scale 15.77 (2.32) 6.55 (1.97) by design
AHI*, (events/h
1
45.53 (19.11) 43.05 (19.23) 0.251
TST*, (min) 351.26 (50.53) 314.83 (72.65) <0.001
% Time with SaO2 <90% 11.95 (21.6) 15.02 (21.05) 0.03
F1 sleep, (%) of sleep 6.26 (9.76) 10.92 (8.65) <0.001
F2 sleep, (%) of sleep 64.95 (13.5) 66.19 (9.71) 0.789
F3 þ F4 sleep, (%) of sleep 14.25 (10.8) 11 (7.84) 0.08
REM sleep, (%) of sleep 15.37 (9.91) 14.33 (6.59) 0.55
Glucose, (mg/dl) 101.74 (18.07) 102.3 (16.96) 0.854
Triglyceridesþ, (mg/dl) 134 (98.75) 125.5 (98.75) 0.521
SBP*, (mm Hg) 131.72 (16.88) 131.08 (15.06) 0.434
DBP*, (mm Hg) 82 (14.05) 82.33 (10) 0.542
Nocturnal heart rate, (bpm) 65.18 (11.07) 64.79 (9.2) 0.743
Cigarette smokers, [n (%)] 40 (15.06) 30 (11.7) 0.257
CRP*, (mg/l) 3.64 (4.84) 3.62 (4.01) 0.473
*EDS; Excessive Daytime Sleepiness, BMI; Body Mass Index, AHI; Apneaehypopnea index, TST; Total sleep time, SBP; Systolic blood
pressure, DBP; Diastolic blood pressure, CRP; C-reactive protein.
þ
Median (IQR).
The statistically significant p values are denoted by bold.
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features of OSA). No differences were found in the plasma
levels of neuropeptide Y, leptin and adiponectin between
these two groups. The present study has the largest number
of patients of any to address this issue so far, and the two
groups included in the study were well characterized for
the presence or absence of daytime sleepiness. These
results could indicate a relationship between EDS in
patients with OSA and plasma levels of hypocretin-1 and
ghrelin, two peptides that participate in metabolic and
sleep regulation.
The origin and function of hypocretin-1 in plasma is
unknown, but it is postulated that plasma hypocretin-1 may
originate from leaks in the bloodebrain barrier and from
peripheral synthesis.18,19 Some authors have reported lower
plasma hypocretin-1 levels in patients with OSA thanFigure 1 Plasma levels of neuropeptides in OSA pacontrols.20e22 Nevertheless, others reported otherwise.23,24
These discrepant findings could be related to the different
populations studied and to methodological issues with
hypocretin-1 assays. These studies also analyzed the
correlation of certain clinical variables associated with OSA
and plasma hypocretin-1 levels. Nishijima et al.21 showed
significant negative correlations with ESS. Nevertheless
others authors did not find a significant correlation with ESS
score.20,23 We found a statistically significant linear corre-
lation between hypocretin-1 and ESS score (Table 2).
Hypocretin-1 is a neuropeptide that influences the
sleepewake cycle, arousal regulation and the maintenance
of the alert state.9 It could be hypothesized that the
increased plasma hypocretin-1 observed in OSA patients
with EDS could indicate a mechanism that facilitate
wakefulness and counteracts the effects of sleepiness.tients with and without EDS (mean  C.I. 95%).
Figure 2 Plasma levels of metabolic hormones in OSA patients with and without EDS (mean  C.I. 95%).
1958 M. Sa´nchez-de-la-Torre et al.Patients with sleep apnea and without EDS would not be
able to activate these mechanisms and therefore OSA
patients would be less susceptible to the effects of sleep
apnea and would not manifest EDS.
Previous studies have analyzed neuropeptide Y plasma
levels in OSA patients. Barcelo´ et al.25 described increased
levels of neuropeptide Y in OSA patients compared with
control subjects. Although plasma neuropeptide Y values
were lower in our patients with EDS than in patients
without EDS, the differences were small and did not ach-
ieve statistical significance (Fig. 2). Plasma neuropeptide Y
levels did not appear to be correlated with clinical factors,
such as BMI, AHI and ESS.
In the present study we also analyzed the relationship
between EDS and plasma levels of three metabolic
hormones: ghrelin, leptin and adiponectin. We found that
plasma ghrelin levels were lower in OSA patients with EDS
than in patients without EDS. Previous studies have shown
that plasma ghrelin levels are higher in patients with OSA
compared to controls.26 Plasma ghrelin levels could be
modulated by, or conversely, modulate EDS in the context
of OSA. Indeed, synthesis of ghrelin hormone is affected by
sleep duration, as shown by Taheri et al., such that short
sleep duration was associated with elevated plasma ghrelin
levels.27 In our study, as might be expected, patients
without EDS, who had higher plasma ghrelin levels than
patients with EDS, were also those with shorter sleep
duration, assessed by total sleep time. After adjustment forTable 2 Linear correlation values for the analysis of neuropep
variables.
BMI
Hypocretin-1 r Z 0.03
p Z 0.69
Neuropeptide Y r Z 0.01
p Z 0.92
Ghrelin r Z 0.155
p Z 0.01
Leptin r Z 0.368
p< 0.001
Adiponectin r Z 0.1
p Z 0.11
*BMI; Body mass index, ESS; Epworth sleep scale, AHI; Apneaehypopn
The statistically significant p values are denoted by bold.confounding variables, the relationship between ESS score
and plasma ghrelin levels remained statistically significant.
There was no difference between OSA patients with and
without EDS in plasma levels of leptin. This hormone has
been positively correlated with BMI, suggesting the pres-
ence of leptin resistance in the context of obesity.28 As
expected, we found a significant positive correlation
between BMI and plasma leptin levels in our study (Table 2).
We did not find any significant differences in plasma leptin
levels between OSA patients with and without EDS. We also
did not find any differences in plasma adiponectin levels
between these two groups.
In the present study ESS score was not associated with
AHI and BMI. The possible correlation between daytime
sleepiness and AHI is unclear.1,29e31 Previous studies have
also indicated an association between BMI and EDS, but we
did not find this association in our study. Bixler et al.32
described an association between EDS and BMI in the
general population with a BMI between 18 and 69 kg m2.
Nevertheless, our study population of OSA patients may be
different from the general population. Also, in Bixler et al.
the presence of EDS was established based on a moderate
or severe rating on either of two questions. Nevertheless, in
our study we performed a more accurate daytime sleepi-
ness characterization using the Spanish validated version of
the Epworth Sleepiness Scale (ESS).14 In the present study,
we also found a statistically significant relationship
between ghrelin and hypocretin-1 levels with the totaltides/metabolic hormones, and clinical and anthropometric
ESS AHI
r Z 0.3 r Z 0.07
p< 0.0001 p Z 0.23
r Z 0.08 r Z 0.06
p Z 0.18 p Z 0.29
r Z 0.236 r Z 0.083
p< 0.001 p Z 0.17
r Z 0.03 r Z 0.001
p Z 0.73 p Z 0.81
r Z 0.03 r Z 0.02
p Z 0.93 p Z 0.82
ea index.
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an association but we cannot indicate causality.
The present study has several strengths: its multicentric
design, close matching of study subjects for gender, age,
BMI and AHI, and large sample size. In addition, the
exclusion of patients with ESS scores in the range where
substantial overlap occurs allowed for better demarcation
of those patients with EDS and those without EDS. However,
our study has several limitations that deserve comment:
First, sleepiness was assessed using subjective methods,
rather than using a multiple sleep latency test. As
mentioned, we did not include patients in the study with
ESS scores between 10 and 12, in order to improve the
discriminatory value of the Epworth score. Second, in the
present study, the associations between metabolic
hormones and neuropeptides were analyzed from a single
morning sample, rather than from multiple samples within
the circadian cycle. Third, we did not include the treat-
ment effect. An interventional study would enable better
discrimination of the strength of the associations described
herein and would enable confirmation of their validity.
Indeed, if improvements in sleepiness were predicted by
changes in any of these plasma markers or combinations
thereof, the intrinsic roles and clinical value of such assays
would be greatly enhanced.
Conclusions
Our study shows that EDS in patients with OSA is associated
with increased circulating hypocretin-1 and decreased
circulating ghrelin levels, two peptides involved in the regu-
lation of body weight, energy balance, sympathetic tone and
sleepewake cycle. This relationship is independent of AHI
and obesity (two key phenotypic features of OSA).
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